Tuning protein synthesis for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Activating mutations in the KRAS proto-oncogene occur in approximately 50% of colorectal cancers.
• KRAS-mutated tumors are notoriously difficult to treat with current therapies.
• KRAS activation influences cellular processes beyond simple proliferation.

Purpose of the Study:

• To investigate the downstream effects of KRAS activation on mRNA translation and protein synthesis.
• To explore the role of c-MYC (MYC proto-oncogene) in KRAS-driven colorectal cancer.
• To identify potential therapeutic vulnerabilities in KRAS-mutated colorectal cancer.

Main Methods:

• Analysis of mRNA translation regulation in KRAS-mutated cancer models.
• Quantification of total protein synthesis rates.
• Assessment of c-MYC expression levels.
• Evaluation of therapeutic strategies targeting downstream pathways.

Main Results:

• KRAS protein activation was found to dysregulate mRNA translation.
• This dysregulation leads to increased overall protein synthesis.
• Elevated expression of the c-MYC proto-oncogene is maintained by activated KRAS.
• Targeting these downstream pathways demonstrated significant anti-cancer effects.

Conclusions:

• KRAS-mutated colorectal cancers exhibit a dependency on altered mRNA translation and elevated c-MYC.
• These findings highlight novel therapeutic targets downstream of KRAS.
• Targeting these pathways presents a potential clinical strategy for treating KRAS-driven colorectal cancer.